FAQ: What Medical Cannabis Stakeholders Should Know About the DEA Marijuana Scheduling Hearing

Posted by 1592.40pc on June 29, 2026

The DEA marijuana (cannabis) scheduling hearing that begins today has created a lot of confusion for patients, caregivers, advocates, businesses, and state regulators.

Some people are asking why so many anti-cannabis voices are testifying. Others are treating the hearing as if it could legalize adult-use cannabis or replace the need for DEA registration. Some regulators appear to be waiting for the hearing instead of helping eligible medical cannabis businesses prepare for the new federal medical cannabis pathway.

This FAQ includes information medical cannabis stakeholders need to know, including what the hearing can and cannot do, and why we need to act now (not after the hearing) to protect and expand safe access.

Click Here to Read ASA's FAQ

 

 

Previous
Federal Cannabis Reform Is Moving, but States Have a Fast-Approaching Deadline to Protect Patient Access
Monthly Donor Button